Krishna Institute of Medical Sciences Ltd logo

Krishna Institute of Medical Sciences Ltd

KIMS NSE

Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.

AI Verdict: HOLD Confidence: 5%

KIMS enjoys unanimous analyst buy ratings (13/13) and strong revenue growth of 21-29% CAGR, but the stock trades at an extremely expensive PE of 130.8x with a TTM profit decline of -32%. At 14.09x book value with no dividend and declining promoter holding, the risk-reward is unfavorable for fresh entry despite solid operational momentum.

Key Fundamentals

Volatility
Moderate
P/E Ratio
132.12
EBITDA
₹791 Cr
Return on Equity
16.05%
Debt to Equity
0.99
EPS
₹39.48
52W High
₹818
52W Low
₹575.8

Technical Indicators

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company's median sales growth is 21.9% of last 10 years

Weaknesses

4
  • Stock is trading at 14.2 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -4.73%

Growth Rate

Revenue Growth
27.31% ↗
Net Income Growth
-52.34% ↘
Cash Flow Change
11.65% ↗
ROE
6.85% ↗
ROCE
-11.21% ↘
EBITDA Margin (Avg.)
-24.35% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk high

KIMS enjoys unanimous analyst buy ratings (13/13) and strong revenue growth of 21-29% CAGR, but the stock trades at an extremely expensive PE of 130.8x with a TTM profit decline of -32%. At 14.09x book value with no dividend and declining promoter holding, the risk-reward is unfavorable for fresh entry despite solid operational momentum.

Bull Case 8
  • Unanimous analyst consensus with 100% buy ratings (13 out of 13 analysts) signals strong institutional conviction
  • Compounded sales growth of 29% TTM and 21% 3-year CAGR demonstrates robust top-line momentum in a secular healthcare growth market
  • 10-year median sales growth of 21.9% reflects consistent long-term revenue compounding ability
  • Stock CAGR of 30% over 3 years and 27% over 1 year shows sustained wealth creation for shareholders
  • 5-year ROE average of 18% indicates historically efficient capital deployment in a capital-intensive hospital business
  • Market cap of Rs 31,745 Cr provides adequate liquidity and institutional ownership eligibility
  • Company is expected to deliver a good upcoming quarter, suggesting near-term earnings catalyst
  • 10-year compounded profit growth of 25% shows long-term earnings power despite recent cyclical softness
Bear Case 8
  • PE ratio of 130.8x is excessively expensive even for a high-growth healthcare name, leaving minimal margin of safety
  • TTM profit declined -32% year-over-year, indicating severe near-term earnings compression despite revenue growth
  • 3-year compounded profit CAGR of -9% shows earnings have been shrinking on a medium-term basis
  • Price-to-book of 14.09x is extremely rich and suggests the stock prices in years of flawless execution
  • Zero dividend yield despite repeated profitability signals poor capital return policy for shareholders
  • Promoter holding has decreased by 4.73% over 3 years, raising concerns about insider confidence
  • Last year ROE dropped to 11% from 5-year average of 18%, a 39% deterioration in return efficiency
  • Company might be capitalizing interest costs, potentially flattering reported profitability and asset values

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Headwinds 4
  • FY26 net profit down 37% Jun 9

    Full-year net profit declined 37.22% to ₹241.40 crore against ₹384.50 crore in the previous year, despite revenue growing 28.65% to ₹3,904.60 crore.

  • EBITDA margins compressing sharply Jun 9

    Operating margins fell to 19.22% in Q3 FY26 from 24.85% in the prior quarter, reflecting operational challenges from new units and expansion activities.

  • Q4 FY26 profit crashes 58% Jun 13

    Consolidated net profit declined 58.25% to ₹42.50 crore in Q4 FY26 despite a 34.85% revenue increase to ₹1,074.60 crore, indicating severe margin pressure.

  • Potential equity dilution ahead Jun 16

    KIMS opened a QIP at ₹771.73 floor price targeting ₹1,500 crore raise, and separately approved ₹599.99 crore in warrants to promoters — combined dilution could be significant.

Positives 4
  • ₹600 cr promoter warrant issue Jun 13

    Board approved 77.02 lakh warrants at ₹779/warrant to promoter group aggregating ₹599.99 crore, signaling strong promoter confidence. Stock surged 22.05% on the news.

  • ₹1,500 cr QIP for growth Jun 9

    Board approved a ₹1,500 crore QIP to strengthen the balance sheet and fund expansion across 25 hospitals in 6 states, with new capacity in Chennai and Amravati.

  • Revenue growth robust at 29% Jun 9

    Revenue grew 29.17% YoY to ₹997.70 crore in Q3 FY26 and 28.65% for full-year FY26 to ₹3,904.60 crore, demonstrating strong top-line momentum from network expansion.

  • Promoter stake rising to 35.35% Jun 13

    Post warrant conversion, promoter and promoter group holding will increase from 34.11% to 35.35%, reinforcing alignment with minority shareholders.

Neutral 6
  • ₹57 cr block trade on NSE Jun 22

    Approximately 7.10 lakh shares traded at ₹807.40/share for ₹57.31 crore, indicating institutional-level activity in the stock.

  • ₹17 cr block trade on NSE Jun 10

    About 2.22 lakh shares traded at ₹781.90/share for ₹17.36 crore, reflecting institutional participation.

  • FY26 audited results filed Jun 16

    KIMS filed audited standalone and consolidated financials for FY26 with statutory auditors confirming adequate internal financial controls.

  • Promoter pledge status disclosed Jun 11

    No new encumbrances reported for FY26; Dr. Bhaskara Rao Bollineni holds 1.4 crore pledged shares with no change in status.

  • Analyst meets scheduled Aug 13-14 Jun 5

    KIMS will host analyst and institutional investor meetings in Mumbai on August 13-14, 2026. No UPSI will be shared.

  • Board met Jun 13 for fundraise Jun 10

    Board meeting held June 13 to consider raising funds via equity shares or other securities, with EGM planned for July 9 for shareholder approval.

TL;DR: KIMS is growing revenue aggressively at ~29% YoY driven by hospital network expansion to 25 facilities, but profitability has deteriorated sharply with FY26 net profit down 37% and EBITDA margins compressing from ~24% to ~19%. The company is raising ~₹2,100 crore combined (QIP + warrants) to fund growth, with strong promoter participation signaling confidence. The key question is whether margin recovery materializes as new hospitals mature — if it does, the revenue base supports significant earnings upside, but near-term dilution and profit decline remain overhangs.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
576
606
652
606
634
688
777
772
797
872
961
998
1,075
Expenses
413
449
475
459
475
509
559
585
599
679
757
799
868
Operating Profit
163
157
177
147
159
179
218
187
198
193
204
199
206
OPM %
28%
26%
27%
24%
25%
26%
28%
24%
25%
22%
21%
20%
19%
Other Income
5
3
3
3
4
5
5
18
15
7
4
5
1
Interest
5
9
9
12
16
18
20
26
27
33
45
57
68
Depreciation
35
32
33
35
46
39
41
45
53
53
66
79
85
PBT
127
119
139
102
100
127
162
135
134
114
97
69
55
Tax %
22%
27%
27%
25%
28%
25%
26%
31%
21%
25%
26%
24%
40%
Net Profit
99
87
101
77
72
95
121
92
106
85
72
52
33
EPS in Rs
2.33
2.02
2.3
1.8
1.64
2.16
2.68
2.22
2.54
1.96
1.67
1.33
1.06
Figures in ₹ Crores

Profit & Loss

  Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
512
567
664
918
1,123
1,330
1,651
2,198
2,498
3,035
3,905
Expenses
403
450
593
833
872
953
1,126
1,587
1,850
2,242
3,103
Operating Profit
109
118
71
85
251
377
524
611
648
793
802
OPM %
21%
21%
11%
9%
22%
28%
32%
28%
26%
26%
21%
Other Income
5
3
37
6
5
9
27
41
13
43
18
Interest
37
32
88
49
44
37
22
37
55
100
202
Depreciation
36
35
40
56
71
70
73
129
147
177
283
PBT
41
53
-20
-15
141
279
457
485
460
558
334
Tax %
32%
37%
126%
223%
18%
26%
25%
25%
27%
26%
28%
Net Profit
28
33
-46
-49
115
205
344
366
336
415
242
EPS in Rs
0.76
0.91
-1.32
-1.28
3.2
5.19
8.32
8.41
7.75
9.61
6.03
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

  Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
70
72
50
74
74
78
80
80
80
80
80
Reserves
193
255
-209
466
524
786
1,307
1,590
1,748
2,058
2,167
Borrowings
256
280
753
336
369
316
257
678
1,355
2,557
4,253
Other Liabilities
146
167
359
237
228
253
260
553
636
995
1,258
Total Liabilities
665
774
954
1,114
1,194
1,433
1,904
2,901
3,820
5,689
7,759
Fixed Assets
515
518
755
863
916
931
1,005
1,766
2,434
3,348
5,710
CWIP
2
64
0
0
2
9
21
477
600
1,214
606
Investments
11
14
0
0
0
0
332
68
157
99
103
Other Assets
137
177
199
250
276
493
546
590
629
1,028
1,339
Total Assets
665
774
954
1,114
1,194
1,433
1,904
2,901
3,820
5,689
7,759
Figures in ₹ Crores

Cash Flow

  Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
95
82
106
134
202
356
324
432
521
582
511
Investing
-41
-100
-64
-110
-125
-354
-412
-416
-753
-1,116
-1,452
Financing
-65
24
-39
-27
-44
10
61
20
217
543
940
Net Cash Flow
-11
5
3
-3
32
12
-26
36
-15
9
-1
Free Cash Flow
61
-18
49
57
150
262
154
-140
-125
-380
-902
CFO/OP
88
80
192
195
102
104
86
87
102
91
83
Figures in ₹ Crores

Ratios

  Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
47
59
59
49
43
30
28
42
43
48
52
Inventory Days
36
43
46
47
44
30
37
—
—
—
44
Days Payable
194
207
215
181
177
167
133
—
—
—
146
Cash Conversion Cycle
-111
-105
-110
-85
-91
-106
-67
42
43
48
-50
Working Capital Days
11
26
-333
-15
-15
-31
-3
8
-5
-29
-35
ROCE %
—
15%
11%
5%
20%
29%
34%
24%
17%
15%
9%

Shareholding Pattern

As of Mar 2026
Promoters 34.11%
DIIs 32.50%
Public 18.82%
FIIs 14.57%
Total 100.00%
  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
38.85%
38.85%
38.82%
38.82%
38.82%
38.82%
38.82%
38.82%
34.11%
34.11%
34.11%
34.11%
FIIs
13.15%
14.24%
15.27%
16.73%
17.84%
15.85%
15.68%
15.44%
15.54%
15.03%
14.33%
14.57%
DIIs
35.77%
34.80%
34.24%
33.13%
32.12%
32.29%
32.05%
31.95%
31.65%
32.12%
32.72%
32.50%
Public
12.23%
12.10%
11.67%
11.32%
11.22%
13.03%
13.45%
13.78%
18.68%
18.74%
18.85%
18.82%
No. of Shareholders
65,449
66,957
71,014
69,092
69,063
77,617
95,468
1,01,895
1,08,955
1,04,872
1,01,599
93,333

Documents

Frequently Asked Questions about Krishna Institute of Medical Sciences Ltd

What does Krishna Institute of Medical Sciences Ltd do?
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and...
Where is Krishna Institute of Medical Sciences Ltd (KIMS) listed?
Krishna Institute of Medical Sciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: KIMS and BSE: 543308. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Krishna Institute of Medical Sciences Ltd belong to?
Krishna Institute of Medical Sciences Ltd operates in the Healthcare sector within the Healthcare Services industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the PE ratio of Krishna Institute of Medical Sciences Ltd?
The Price-to-Earnings (PE) ratio of Krishna Institute of Medical Sciences Ltd is 132.12. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Krishna Institute of Medical Sciences Ltd?
Over the past 52 weeks, Krishna Institute of Medical Sciences Ltd has traded between a low of ₹575.8 and a high of ₹818. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Krishna Institute of Medical Sciences Ltd?
Krishna Institute of Medical Sciences Ltd has a Return on Equity (ROE) of 16.05%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Krishna Institute of Medical Sciences Ltd on Tapetide?
On Tapetide, you can view Krishna Institute of Medical Sciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.

Website kimshospitals.com
Listed 2021-06-28
Face Value ₹ 2
Issued Size 40,01,38,935

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List